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Development of Quality Indicators for the Antibiotic
Treatment of Complicated Urinary Tract Infections:
A First Step to Measure and Improve Care
H. S. Hermanides,1 M. E. J. L. Hulscher,2 J. A. Schouten,2 J. M. Prins,1 and S. E. Geerlings1
1Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine & AIDS, Center for Infection and Immunity Amsterdam,
Academic Medical Center, Amsterdam, and 2Centre for Quality of Care Research, Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands
Background. Appropriateness of antibiotic treatment of urinary tract infection (UTI) is important. The aim
of this study was to develop a set of valid, reliable, and applicable indicators to assess the quality of antibiotic use
in the treatment of hospitalized patients with complicated UTI.
Methods. A multidisciplinary panel of 13 experts reviewed and prioritized recommendations extracted from
a recently developed evidence-based national guideline for the treatment of complicated UTI. The content validity
was assessed in 2 consecutive rounds with an in-between discussion meeting. Next, we tested the feasibility,
interobserver reliability, opportunity for improvement, and case-mix stability of the potential indicators for a data
set of 341 inpatients and outpatients with complicated UTIs who were treated at the urology or internal medicine
departments at 4 hospitals.
Results. The panel selected and prioritized 13 indicators. Four and 9 indicators were performed satisfactorily
in the urology and internal medicine departments, as follows: performance of urine culture, prescription of
treatment in accordance with guidelines, tailoring of treatment on the basis of culture results, and a switch to oral
treatment when possible in the urology and internal medicine departments; and selective use of fluoroquinolones,
administration of treatment for at least 10 days, prescription of treatment for men in accordance with guidelines,
replacement of catheters in patients with UTI, and adaptation of the dosage on the basis of renal function in the
internal medicine department.
Conclusion. A systemic evidence- and consensus-based approach was used to develop a set of valid quality
indicators. Tests of the applicability of these indicators in practice in different settings is essential before they are
used in quality-improvement strategies.
Urinary tract infections (UTIs) are among the most
common infections in patients seen in the hospital [1].
Consequently, a significant portion of overall antimi-
crobial use in hospitals is for treatment of UTIs. Re-
sistance rates for Escherichia coli and other uropatho-
gens to trimethoprim (with and without sulfa-
methoxazole) and other antibiotics have been increas-
ing in recent years in many countries of the world [2,
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3]. Therefore, guidelines for the treatment of UTIs have
to be updated regularly and subsequently implemented
[4–6]. Previous studies have demonstrated that adher-
ence to guidelines on antibiotic use improves outcome
[7, 8].
The quality of care can be measured by indicators,
which can be defined as retrospectively measurable el-
ements of practice performance for which there is evi-
dence or consensus that they can be used to assess the
quality of care—and, thus, leads to changes in the qual-
ity of care provided [9]. To our knowledge, no quality
indicators have been developed for antibiotic use in
hospitalized patients with complicated UTI.
The aim of our study was to develop a valid set of
applicable indicators to measure the quality of care for
antibiotic treatment of complicated UTI. We used our
recently written, evidence-based national guidelines as
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Table 1. Level of supporting evidence.
Level of
supporting evidence Definition Example
A1 A good systematic review of studies designed to
answer the question of interest
Systematic review of randomized, controlled trials
A2 One or more rigorous studies designed to answer
the question but not formally combined
Randomized, controlled trial
B One or more prospective clinical studies that illuminate
but do not rigorously answer the question
Prospective cohort study; unpowered or poor
quality randomized, controlled trial; or nonran-
domized, controlled trial
C One or more retrospective clinical studies that illuminate
but do not rigorously answer the question
Audit or retrospective case-control study
D Formal combination of expert views or other information Delphi study; expert opinion; informed consensus
NOTE. Data are from [10].
a starting point [6]. The indicator set was tested in 4 hospitals
to provide an applicability test for daily practice.
METHODS
Phase 1: Development of Indicators
Key recommendations were preselected from a recently devel-
oped, evidence-based national guideline on the antimicrobial
treatment of complicated UTI in patients seen in the hospital
(inpatients and outpatients) (http://www.swab.nl) [6]. On the
basis of the available literature, the level of evidence was graded
for each recommendation to determine its scientific soundness
or the likelihood that improvement for the quality indicator
would produce consistent improvements in the quality of care
(table 1) [11]. Key recommendations supported by a level of
evidence with a grade of A were selected as content validity
indicators. To assess the validity of recommendations supported
by grade B–D supporting evidence, we used the group judge-
ment of expert opinions with a 3-step modified Delphi ap-
proach [12]. Therefore, we assembled a multidisciplinary as-
sessment team with representatives of all involved clinical
experts, as described elsewhere [11, 13]. The expert panel con-
sisted of 13 panelists: 2 medical microbiologists, 4 infectious
diseases specialists, 2 hospital pharmacists, 2 urologists, 2 ne-
phrologists, and 1 gynecologist. During 3 rating rounds, the
expert panel rated the preselected recommendations by judging
their relevance with regard to patient health, development of
bacterial resistance, and health care cost.
During the first rating round, the preselected recommen-
dations were formatted as a questionnaire, and the panelists
were asked to rate each potential indicator using a 9-point
Likert scale (with 1 denoting “definitely not appropriate care”
and 9 denoting “definitely appropriate care”) and were asked
to add additional recommendations for consideration or sug-
gestions and comments. Between the first and second round,
a panel meeting took place, during which each panelist was
provided with an overview of the first round’s ratings. Rec-
ommendations rated with an overall median score of 8 and 9,
without disagreement, were considered to be face valid and
reliable [14] and were thus selected as preliminary indicators.
Disagreement was defined as the occurrence of30% of scores
in both the bottom [1–3] and the top [7–9] tertile [15]. Rec-
ommendations with an overall median rating of 1–3 were con-
sidered to range from invalid to equivocal. Newly added rec-
ommendations, recommendations with an overall median
rating of 4–6 or of 7 with agreement, and recommendations
with an overall median rating of 8 or 9 with disagreement were
discussed and reformulated when necessary.
After the meeting, all of the discussed and reformulated rec-
ommendations (plus additional recommendations) were for-
matted again as a questionnaire, and the panelists were asked
to rate these again. The final selection was made by asking the
panel members to prioritize the potential indicators by selecting
the “top 5” most important potential indicators, which were
selected in the final set if prioritized by 2 panelists. These
prioritized potential indicators were further developed into in-
dicators by defining numerators and denominators [16].
Phase 2: Applicability Testing
Before the indicator set was used in a specific setting (e.g., as
part of an improvement project in a specific hospital or in a
study including several hospitals aiming at comparing and im-
proving the quality of antibiotic treatment of UTI), the appli-
cability of each indicator had to be tested. So, in each practice
setting chosen, the next step was to provide empirical evidence
of feasibility, interobserver reliability, opportunity for improve-
ment, and case-mix stability for each indicator (figure 1).
We tested the applicability of the indicator set at 4 (1 uni-
versity and 3 nonuniversity) medical centers in Amsterdam,
The Netherlands: Academic Medical Center, Onze Lieve
Vrouwe Hospital, Sint Lucas Andreas Hospital, and BovenIJ
Hospital. To assess whether applicability was different in dif-
ferent types of wards, we decided to study the internal medicine
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Figure 1. Procedural flow chart showing the development of quality indicators (phase 1) and their applicability testing in practice (phase 2). “Not
feasible” means that there were not enough data available to evaluate the indicator. “Not reliable” means that the interobserver reliability was too
low. “No room for improvement means” that the performance score of the indicator was already high. “Minimum sample size” means that the indicator
could be evaluated in a minimal sample size of patients.
and urology departments separately. We included the same cat-
egories of patients as in our recently written, evidence-based
national guideline [6].
Eligible patients included inpatients and outpatient aged 112
years who were treated with antibiotics for a complicated UTI
during the period from January 2005 through July 2006. A
patient with an uncomplicated UTI was defined as an im-
munocompetent, nonpregnant woman who had cystitis, with-
out symptoms of tissue invasion or systemic infection and with-
out any functional or anatomical abnormalities of the urinary
tract. All other UTIs were considered to be complicated UTIs
[17]. Patients with uncomplicated UTI, nosocomial infection,
or infection that occurred after a urological procedure were
not described in the guideline and were therefore excluded. The
identification of patients was performed using the national di-
agnosis registration system. Subsequent manual screening took
place, with use of medical and nursing records, admission
sheets, medication charts, and laboratory and culture results.
Both inpatients and outpatients were eligible.
Feasibility. For every indicator, feasibility was defined as
the availability of administrative data required to evaluate the
indicator. An indicator was considered to be feasible if the data
















1. Perform a urine culture
Internal medicine 191 16 82 (0.60–0.90) 1 No
Urology 150 18 75 (0.75–0.84) 1 Yesa,b
2. Prescribe empirical therapy in accordance with
the national guideline
Internal medicine 151 1 73 (0.31–0.81) 0.89 Yesc
Urology 46 0 36 (0.31–0.38) 1 Yesa
3. Use fluoroquinolones only as oral therapy or be-
cause of anaphylaxis related to b-lactam
antibiotics
Internal medicine 22 18 63 (0.33–0.83) 0.67 No
Urology 37 3 94 (0.90–1.00) 1 NA
4. Change empirical therapy to pathogen-directed
therapy when culture results become available
Internal medicine 182 9 53 (0.26–0.70) 0.87 No
Urology 117 19 44 (0.28–0.48) 1 Yesa,d
5. Change from intravenous to oral therapy after
48–72 h on the basis of the clinical condition
Internal medicine 155 26 31 (0.23–0.34) 0.85 No
Urology 30 27 27 (0.20–0.33) 1 No
6. Duration of antibiotic therapy should be at least
10 days.
Internal medicine 191 8 47 (0.40–0.90) 0.78 No
Urology 150 15 66 (0.62–0.79) 0.58 Yesb,d
7. Initiate antibiotic treatment within 4 h after clini-
cal presentation
Internal medicine 191 75 11 (0.02–0.20) 0.6 NA
Urology 150 93 5 (0.00–0.08) 1 NA
Men
8. Prescribe all men empirical therapy in accor-
dance with the national guideline
Internal medicine 45 4 80 (0.25–0.89) 1 NN
Urology 13 8 50 (0.17–1.00) ND NA
Pregnant women
9. Start intravenous antibiotic therapy in pregnant
women with pyelonephritis
Internal medicine 0 NM NM NM NM
Urology 0 NM NM NM NM
Patients with a urinary catheter in place
10. Do not prescribe antibiotic prophylaxis to pa-
tients with a urinary catheter
Internal medicine 28 0 100 (0.83–1.00) 1 NA
Urology 9 22 50 (0.25–1.00) ND NA
11. Change catheter within 24 h after initiation of
antibiotic treatment
Internal medicine 34 26 14 (0.14–0.33) ND NN
Urology 9 33 0 (0.00–0.50) ND NA
Patients with diabetes mellitus
12. Consider all diabetic patients with cystitis as
having a complicated UTI and prescribe empir-
ical treatment in accordance with the national
guideline
Internal medicine 6 0 33 (0.00–1.00) ND NA
Urology 12 17 0 (0.00–0.00) ND NA
(continued)















Patients with renal insufficiency
13. Adapt dose of antibiotics on the basis of renal
function
Internal medicine 74 5 45 (0.29–0.64) 1 NN
Urology 10 30 33 (0.00–0.43) 0.63 NA
NOTE. See Methods for definitions. The final indicators that were applicable in practice are shown in boldface font. NA, not applicable; ND,
not enough data available; NM, not measurable (for this indicator, there were no patients represented in the sample); NN, not necessary; UTI,
urinary tract infection.
a Correction for sex required.
b Correction for comorbidity (urologic medical history) required.
c Correction for age required.
d Correction for comorbidity (cardiovascular disease) required.
necessary to score the indicator could be abstracted from the
available data for 170% of cases [18].
Interobserver reliability. Interobserver reliability was mea-
sured to assess the reproducibility between observers and be-
tween cases. A second investigator rated 10% of all the records
of the participating departments of the 4 medical centers. To
assess the agreement between the 2 investigators corrected for
chance, k coefficients were calculated. Indicators for which
were considered to be unreliable [19].k ! 0.60
Potential room for improvement. “Potential room for im-
provement” was defined as the sensitivity of a potential indi-
cator to detect variability and changes in the quality of care
between and within cases. A potential indicator with an in-
variable high performance score does not discriminate quality
of care between and within cases. Potential indicators with a
median performance score of 185% were defined as having
little interdepartmental and interhospital variation and were
therefore considered to have little room for improvement [20].
Sample size. The applicability of an indicator is also de-
pendent on the number of patients on which it can be applied.
Considering the period of inclusion and the number of wards
studied, we considered an indicator to be applicable if it had
a minimum sample size of 20 patients for the 4 internal med-
icine departments and of 15 patients for the urology
departments.
Case-mix stability. The relationship between certain pa-
tient characteristics and the result for the indicator was analyzed
using logistic regression analysis. Indicators that are not “case-
mix stable” require comparable patient populations when com-
paring the quality of care in time or between settings. Indicators
for specific subpopulations (i.e., indicators 8–13) (table 2) did
not need correction for case mix, because we assumed that the
subpopulations already accounted for a more homogenous
population for different hospital sizes and settings. We studied
the distribution of outcome of the general indicators (i.e., in-
dicators 1–7) (table 2) on the basis of age, sex, the presence of
systemic symptoms, and comorbidities (cardiovascular disease
and urological medical history) at first clinical presentation.
RESULTS
Phase 1: Development of Indicators
Two infectious diseases specialists (S.E.G. and J.M.P.) and 1
quality-of-care specialist (M.E.L.J.H.) independently prese-
lected 39 key recommendations from the national guideline
(table 3). None of the key recommendations were supported
by grade A evidence. Of the 13 panelist who agreed to partic-
ipate, all completed the questionnaires for rounds 1 and 2.
Eight panelists (62%) were present at the face-to-face panel
meeting. Twelve panelists (92%) responded to the prioritizing
round, in which 11 panelists provided a top 5 priority list and
1 panelist provided a top 3 priority list.
After the first rating round, 26 recommendations were ac-
cepted as preliminary indicators. Thirteen recommendations
were discussed and reformulated during the panel meeting. One
recommendation was added (recommendation 40). After the
second rating round, there were no recommendations with an
overall median rating of 4–6, and consensus was reached for
7 of the revised and newly added recommendations, resulting
in 33 potential indicators for the prioritizing round. A final set
of 13 potential indicators was prioritized (table 2).
Phase 2: Applicability Testing
Applicability testing (figure 1) of the set of indicators in the 4
specific hospitals started in July 2006 and ended in November
2006. Seven of the 8 approached departments participated. A
total of 341 patients were studied. In the internal medicine
departments, nearly all patients (190 of 191) were hospitalized,
and the majority of patients (112 of 150) in the urology de-
partment came from the outpatient clinics. As to be expected,
in the internal medicine department, complicated UTIs in-
cluded pyelonephritis (48 of 191 patients), urosepsis (50 pa-










1. Perform a urine culture D Retained … 10 Selected
2. Perform 2 blood cultures D Discussed Rejected … …
3. Prescribe empirical therapy in accordance with the national guideline. …b Retained … 5 Selected
4. Avoid long-term treatment (172 h) with aminoglycosides D Retained … 1 …
5. Use cephalosporin in cases of hypersensitivity to penicillin derivatives (rash) B Discussed Retained 0 …
6. Use fluoroquinolones only as oral therapy or because of anaphylaxis related to
b-lactam antibiotics
B Discussed Retained 3 Selected
7. Change empirical therapy to pathogen-directed therapy when culture results be-
come available
B Retained … 8 Selected
8. Change from intravenous to oral therapy after 48–72 h on the basis of the clinical
condition
B Retained … 3 Selected
9. Duration of antibiotic therapy should be at least 10 days B Retained … 4 Selected
10. In male patients, urine culture with growth of 103 cfu/mL should be interpreted
as a positive result
B Discussed Rejected … …
11. Prescribe all men empirical therapy in accordance with the national guideline D Retained … 3 Selected
12. The duration of therapy in men with chronic bacterial prostatitis should be at
least 28 days
D Retained … 1 …
13. In patients with suspected chronic bacterial prostatitis, start antibiotic treatment
only after culture results become available
D Discussed Rejected 1 …
14. Chronic bacterial prostatitis should be treated with fluoroquinolones or TMP-SMX B Retained … 0 …
15. Pregnant women with cystitis should be treated with amoxicillin–clavulanic acid
or nitrofurantoin (not during delivery)
C Retained … 0 …
16. The duration of antibiotic therapy for cystitis during pregnancy should be at least
5 days
B Retained … 1 …
17. Pregnant women with pyelonephritis should be hospitalized D Discussed Rejected … …
18. Start intravenous antibiotic therapy in pregnant women with pyelonephritis D Discussed Retained 2 Selected
19. Pregnant women with pyelonephritis should be treated with amoxicil-
lin–clavulanic acid or a second- or third-generation cephalosporin
D Retained … 0 …
20. The duration of antibiotic therapy for pyelonephritis during pregnancy should be
at least 10 days
B Retained … 0 …
21. Perform urine culture after antibiotic treatment of UTI during pregnancy D Retained … 0 …
22. Start antibiotic prophylaxis during delivery when GBS is cultured from a urine
specimen obtained from a pregnant woman
B Retained … 1 …
23. Consult a gynecologist if a urine culture yields GBS for a pregnant woman D Retained … 0 …
24. Do not prescribe antibiotic prophylaxis to patients with a urinary catheter in place D Retained … 4 Selected
25. The duration of antibacterial therapy in patients with a catheter and local symp-
toms of UTI should be 5 days
D Discussed Rejected … …
26. Prescribe empirical therapy to all patients with a catheter and systemic symp-
toms of UTI in accordance with the national guideline
D Retained … 0 …
27. Patients with long-term use of a catheter should be treated empirically with a
fluoroquinolone or aminoglycoside
D Retained … … …
28. Change the urinary catheter within 24 h after initiating antibiotic treatment B Retained … 4 Selected
29. Do not prescribe antibiotic treatment to patients with a urinary catheter and bac-
teriuria only
D Retained … 0 …
30. Consider all diabetic patients with cystitis to have complicated UTI and prescribe
empirical treatment in accordance with the national guideline
D Discussed Retained 2 Selected
31. Diabetic women with cystitis should be treated with amoxicillin–clavulanic acid
or nitrofurantoin
D Discussed Retained 0 …
32. The duration of antibiotic therapy in diabetic women with cystitis should be 7
days
D Discussed Retained 0 …
33. Prescribe all diabetic patients with systemic symptoms of UTI empirical therapy
in accordance with the national guideline
D Retained … 0 …
34. Adapt the dosage of antibiotics on the basis of renal function D Retained … 2 Selected
35. The duration of antibiotic therapy for patients known to have congenital cystic
kidney disease should be 4–6 weeks
D Retained … 1 …
36. Patients with congenital cystic kidney disease should be treated with a fluoro-
quinolone or with b-lactam antibiotics plus an aminoglycoside as empirical antibi-
otic therapy
D Retained … 0 …
37. Perform repeated catheterization of the bladder or use a catheter for bladder in-
stallation of antibiotics or saline in patients with pyocystis
D Retained … 0 …
(continued)











38. Prescribe systemic antibiotic therapy to patients with pyocystis D Discussed Retained 0 …
39. The duration of antibiotic therapy for pyocystitis should be at least 10 days D Discussed Rejected … …
40. Initiate antibiotic treatment within 4 h after first clinical presentation D Added … 2 Selected
NOTE. Round 1 gives the results of the first questionnaire. “Rejected” means that the recommendation was rejected as potential indicator after round
1. Round 2 gives the results of the second round. “Total panelists” denotes the number of panelists who selected the recommendation in their top 5. GBS,
group B Streptococcus species; TMP-SMX, trimethoprim-sulfamethoxazole; UTI, urinary tract infection.
a Supporting evidence is rated on a scale of A–D (table 1).
b Grading of literature was not possible. Source is the yearly report on the prevalence in The Netherlands of the resistance of uropathogens to antibiotics
during 1998–2004.
tients), and UTI in immunocompromised patients (92 patients,
consisting of 52 diabetic patients, 20 patients who were re-
ceiving immunosuppressive drugs, and 20 patients with kidney
disease), whereas complicated UTIs in the urology department
mainly included acute or chronic prostatitis (67 of 150 patients)
or UTIs in patients with anatomical abnormalities of the uri-
nary tract (108 patients).
One indicator—“start antibiotic therapy intravenously in
pregnant women with pyelonephritis”—could not be tested,
because there were no pregnant women in the study sample.
The applicability of the other 12 indicators was tested and
compared between the urology and internal medicine depart-
ments (table 2).
Feasibility. In the urology departments, 93% of patients
had missing data for indicator 7 (“initiate antibiotics within 4
h after clinical presentation”). Furthermore, indicator 11
(“change catheter after initiating antibiotics”) had moderate
feasibility: 33% of patients did not have enough data to assess
the indicator. In the internal medicine departments, only in-
dicator 7 was determined to have low feasibility: for 75% of
patients, the required data to assess the time of antibiotic ad-
ministration were missing.
Interobserver reliability. Indicator 6 (“duration of therapy
should be at least 10 days”) had a low interobserver reliability
( ) in the urology departments and was therefore re-kp 0.58
jected. In the internal medicine departments, moderate inter-
observer reliability ( ) was noted for indicator 7 (“ini-kp 0.60
tiate antibiotic treatment within 4 h after clinical presentation”).
As described above, this indicator also had low feasibility.
Room for improvement. For the urology departments, in-
dicator 3 (“use fluoroquinolones only as oral therapy or because
of anaphylaxis related to b-lactam antibiotics”) yielded a high
median performance rate (94%) and had little room for im-
provement (range for hospitals, 90%–100%). For the internal
medicine departments, indicator 10 (“do not prescribe pro-
phylaxis for patients using a catheter”) yielded a high median
performance rate (100%) and had little room for improvement
(range for hospitals, 83%–100%).
Minimum number of patients. Five indicators (indicators
8 and 10–13) had a sample size of !15 patients for the urology
departments and were therefore rejected. The indicator con-
cerning diabetic patients (indicator 12) could be applied to a
total of only 6 patients for all 4 internal medicine departments
together.
Case-mix stability. At the urology departments, correction
for sex was necessary for 3 indicators (indicators 1, 2, and 4).
These indicators were more often observed in male patients
than in female patients. Two indicators (indicators 1 and 6)
required correction for patients with a medical history of urol-
ogical disease: indicator 1 was more often “positive” (i.e., it
was followed more often) when the patient had a medical his-
tory of urological disease, but indicator 6 was more often “neg-
ative” (i.e., not followed). Two indicators (indicators 4 and 6)
needed correction for patients who were known to have car-
diovascular diseases: indicator 4 was more often “positive”
when the patient had a medical history of cardiovascular dis-
ease, but indicator 6 was more often “negative.” Because we
assumed that the subpopulations already accounted for a more
homogeneous population throughout different hospital sizes
and settings, no further corrections for case-mix stability were
necessary. At the internal medicine departments, empirical
therapy was more often prescribed in accordance with the rec-
ommendations of the guideline (indicator 2) for elderly patients
than for younger patients.
In sum, as shown in table 2, following the applicability test
of each of the 13 indicators, 4 indicators turned out to be
applicable for our urology departments, and 9 indicators were
applicable for our internal medicine departments. These in-
dicators can currently be used by these departments to measure
and improve the quality of antibiotic care for patients with
complicated UTI.
DISCUSSION
A rigorous selection procedure was used, combining scientific
evidence and expert opinion, to define a valid set of quality
indicators regarding antibiotic treatment for complicated UTIs
in the hospital. The clinical benefit of applying indicators is
that they provide insight into current care. But more impor-
tantly, they reveal deficiencies that need to be corrected to reach
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better outcomes in patients. We developed a set of 13 quality
indicators defining optimal UTI care: 7 general indicators, 1
for men, 1 for pregnant women, 2 for people with a urinary
catheter, 1 for diabetic patients, and 1 for people with kidney
disease.
To our knowledge, this is the first set of quality indicators
for the antibiotic use of complicated UTI in the hospital. The
same procedure was performed by Schouten et al. [20] in 2005,
when they defined a set of 15 indicators for the quality of
antibiotic use in hospitalized patients with lower respiratory
tract infections. We used a more rigorous selection of recom-
mendations by asking the panel to prioritize 5 recommenda-
tions in order, to yield a manageable number of indicators to
test for applicability in daily practice.
Before using the indicators in a specific practice setting, the
next step should always be to test the indicators in the hospital
(or nursing home) where they will be used. In our 4 hospitals,
the applicability differed by department: only the following 4
indicators for both the urology and internal medicine depart-
ments and 5 indicators for the internal medicine departments
alone turned out to be applicable: performance of urine culture,
prescription of treatment in accordance with guidelines, tai-
loring of treatment on the basis of culture results, and switches
to oral treatment when possible for both the urology and in-
ternal medicine departments; and selective use of fluoroquin-
olones, duration of treatment of at least 10 days, prescription
of treatment for men in accordance with guidelines, changing
of the catheter in cases of UTI, and adaptation of dosage on
the basis of renal function for the internal medicine depart-
ment. The remaining indicators could either not be measured
or showed no room for improvement in these specific
departments.
An applicability test in a different setting (e.g., in other Dutch
hospitals or in some hospitals in the United Kingdom or United
States) may yield different outcomes, with different implica-
tions for the hospitals in question. Our applicability test implied
the following: if these 4 hospitals want to measure their care
as described with the indicators that currently lack feasibility,
they first have to improve the registration of patient infor-
mation. If current care could not be measured because the
minimum number of 15 patients could not be reached within
the 18 months of enrollment, the measurement period for these
specific indicators should be expanded to enroll enough pa-
tients to measure care. Regarding the indicators that showed
no room for improvement, the measurement showed that, cur-
rently, no deficiencies need to be corrected in these specific
hospitals.
Our study had several limitations. We used a rigorous pro-
cedure, which combined scientific evidence and expert opinion,
to define a valid set of quality indicators. Recommendations
were extracted from a Dutch guideline and were therefore based
on resistance patterns for uropathogens in The Netherlands; in
general, these resistance patterns are more favorable for most
antimicrobials, compared with those in other countries in Eu-
rope and the United States [21]. Therefore, not all recommen-
dations—especially those concerning the choice of antimicro-
bial agents—can be generalized for other countries; they have
to be fine-tuned for the local situation. In addition, none of
the preselected Dutch guideline recommendations had high
levels of supporting evidence (i.e., level A evidence) (table 1)
that guaranteed quality of care. So, unfortunately, (systematic
reviews of) randomized, controlled trials exist for none of the
indicators that link indicator performance to improved patient
outcome. Therefore, measurement of the impact of the indi-
cators on outcome is an essential next step, to make the effort
to develop these indicators more meaningful. However, al-
though no content validity was available for any recommen-
dation, we aimed at high face validity and reliability by using
a consensus approach that combined scientific evidence and
expert opinion. The composition of the expert panel was care-
fully chosen, taking into account that the composition of the
panel can influence the consensus [22, 23]. We selected experts
of all involved disciplines, originating from different geograph-
ical regions.
A last limitation concerns the applicability test. Our data
collection occurred retrospectively, with use of medical and
nursing records, admission sheets, medication charts, and lab-
oratory and culture results. Most Dutch hospitals do not have
systematic and robust registration systems. Therefore, appli-
cation of indicators to measure and improve patient care is
currently an elaborate, time-consuming activity, hampering the
application of these indicators for monitoring or research
purposes.
Future studies must prove whether the final set of 13 clinical
indicators can be used for an intervention program to improve
the quality of antibiotic use for complicated UTI in the hospital.
Tailored interventions based on low performance scores for the
indicators with different implementation strategies and with
postintervention measurements can demonstrate whether it is
possible to change antibiotic use in the hospital.
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